Abstract:Abstract Objective: In the absence of treatments to halt or reverse symptoms of Alzheimer's disease, early detection may extend the window for meaningful treatment, advanced planning, and coping. Positron emission tomography (PET) scans for amyloid and tau are validated biomarkers of AD, yet results are rarely disclosed to participants due to concerns about negative impacts. While prior studies suggest limited anxiety, depression, or suicidality following biomarker disclosure, no study to date has examined broader psychological impacts of PET amyloid/tau disclosure to symptomatic individuals. Therefore, we explored post-disclosure changes in future time perspective (perceptions of limited time or possibilities left in the future), self-efficacy for managing symptoms, and perceived stigma as a function of result received. Participants and Methods: Forty-three older adults (age = 72.0±6.2 years; education = 16.5±2.6; 88.4% White Non-Hispanic; 48.8% female) participated in the study, of whom 62.8% were diagnosed with mild cognitive impairment (MCI) and the remainder with Dementia of the Alzheimer's type. All participants underwent pre-disclosure biomarker education and decisional capacity assessment, followed by baseline measures. Participants demonstration decisional capacity completed an interactive disclosure session during which they received dichotomous results of their research positron emission tomography (PET) scans for amyloid and tau (elevated versus not elevated for each biomarker). Findings were discussed in relation to presence/absence of Alzheimer's disease, the etiology of their cognitive difficulties, and risk for conversion or further decline. At baseline, immediately following disclosure, and at 1-week follow-up, participants completed several questionnaires: the Future Time Perspective (FTP) scale, a measure of how much the participant sees time as limited, the Self Efficacy for Managing Chronic Disease scale (SECD), and the Stigma Scale for Chronic Illness (SSCI-8), all of which were modified to apply to Alzheimer's disease and associated experiences. Results: The main effects of time (F =1.10, p =.334, A?p 2 =.026), biomarker status (F (1)=3.10, p =.086, Ajp 2 =.070), and the time by biomarker status interaction (F =0.39, p =.661, Ajp 2 =.009) on FTP score was not significant. Though neither time (F =0.07, p =.933, A?p 2 =.002) nor the time by biomarker status interaction (F =2.16, p =.122, Ajp 2 =.050) effect on SECD was significant, being biomarker positive (A+T-/A+T+) was associated with lower self-efficacy (F (1)=5.641, p =.022, Ajp 2 =.121). Neither main effect for time (F =0.15, p =.853, Ajp 2 =.004) or biomarker status (F (1)=0.35, p =.558, A?p 2 =.009) on SSCI-8 was significant. The time by biomarker status interaction was significant ( f =4.27, p =.018, =.096), such that biomarker negative participants experience a transient increase in perceived stigma directly after disclosure that resolves one week later, and biomarker negative participants experience the opposite pattern. Conclusions: Findings suggest that individuals who receive biomarker positive results may feel less competent to manage their symptoms compared to those who are biomarker negative, emphasizing the need for post-disclosure interventions targeting self-efficacy. The effect of disclosure on perceptions of time being limited and on perceived stigma were minimal, even when those results indicate evidence of Alzheimer's disease and risk for clinical progression. These results further support the safety of biomarker disclosure procedures. Future studies should provide longer-term assessment of psychological, behavioral, and clinical outcomes following Alzheimer's disease biomarker disclosure.

Associations of Everyday and Lifetime Experiences of Discrimination With Willingness to Undergo Alzheimer Disease Predictive Testing

Barriers and facilitators to participating in Alzheimer's disease biomarker research in black and white older adults

Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial

Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort

Creating an Unprotected Class: Addressing Legal Risks in the Era of Biologically-Defined Alzheimer's Disease

Reasons for undergoing amyloid imaging among diverse enrollees in the A4 study

External validation of dementia prediction models in Black or African American and White older adults: A longitudinal population‐based study in the United States

Promoting diversity in clinical trials: insights from planning the ALUMNI AD study in historically underrepresented US populations with early symptomatic Alzheimer's disease

8 Perspectives of Self, Stigma, and the Future Following Alzheimer's Disease Biomarker Disclosure in Cognitively Symptomatic Older Adults

Research Participants' Perspectives on Precision Diagnostics for Alzheimer's Disease

Racial and Ethnic Disparities in Participation at Alzheimer's Disease Research Centers

US Adults’ Likelihood to Participate in Dementia Prevention Drug Trials: Results from the National Poll on Healthy Aging

A mixed-methods study of cultural beliefs about dementia and genetic testing among Mexicans and Mexican-Americans at-risk for autosomal dominant Alzheimer's disease

Using Direct-to-Consumer Genetic Testing Results to Accelerate Alzheimer Disease Clinical Trial Recruitment

Associations between self-referral and health behavior responses to genetic risk information

The Bio-Hermes Study: Biomarker database developed to investigate blood-based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer's disease

Understanding Barriers and Facilitators to Signing Up for a Mobile-Responsive Registry to Recruit Healthy Volunteers and Members of Underrepresented Communities for Alzheimer's Disease Prevention Studies

Derivation of Indices of Cognitive Change Among Hispanic Adults and Elders

Alzheimer’s Disease Biomarker Decision-Making among Patients with Mild Cognitive Impairment and Their Care Partners

Referral Sources Across Racial and Ethnic Groups at Alzheimer's Disease Research Centers

RACIAL/ETHNIC DIFFERENCES IN SUBJECTIVE COGNITIVE DECLINE (SCD) AND SCD-INDUCED OUTCOMES